The current outbreak of coronavirus disease 2019 (COVID-19), first reported to the World Health Organization (WHO) on December 31, 2019, involves 10,185,374 confirmed cases over 216 countries as of June 30, 2020.^[@ref1]^ The majority of COVID-19 patients develop pneumonia and exhibit symptoms including fever and cough.^[@ref2],[@ref3]^ The genome sequence of the causative agent, a novel coronavirus, was shared through the Global Initiative on Sharing All Influenza Data (GISAID) platform beginning January 12, 2020. The sequences of the novel coronavirus (CoV) are highly similar to those of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV), and like SARS-CoV, the virus uses ACE2 as the entry receptor.^[@ref4]−[@ref6]^ The Coronavirus Study Group of the International Committee on Taxonomy of Viruses designated the virus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).^[@ref7]^

Molecular diagnosis of COVID-19 is currently carried out by one-step quantitative RT-PCR (RT-qPCR) targeting SARS-CoV-2 using primers and probes developed by China CDC, Charité, HKU, Japan NIID, Thailand NIH, and US CDC; these primer--probe sets were posted by the WHO.^[@ref8]−[@ref10]^ Clinical diagnosis methods including CT scanning have also been used to identify COVID-19 cases in Hubei province, China, starting on February 13, 2020.^[@ref11]^ Although the RT-qPCR assay served as a gold-standard method for detecting respiratory infectious viruses such as SARS-CoV and MERS-CoV,^[@ref12]−[@ref15]^ current RT-qPCR assays targeting SARS-CoV-2 have some limitations. First, due to the high similarity between SARS-CoV-2 and SARS-CoV, primer--probe sets cross-react. Second, the sensitivity of these assays may not be sufficient to confirm suspicious patients at early time points after admission. Indeed, several cases have been reported in which CT scan results were positive but RT-PCR results were negative at initial presentation.^[@ref16]^ The performance of molecular diagnostics might depend on primers, probes, and reagents. Previous studies have been reported to compare some primer--probe sets listed in the WHO for the molecular diagnosis of SARS-CoV-2.^[@ref17],[@ref18]^

In this study, we performed RT-qPCR analysis with previously reported specific primer--probe sets targeting the RdRp/Orf1 and N region of SARS-CoV-2. We report here our results comparing the performance of SARS-CoV-2 molecular detection using three different primer--probe sets for the RdRp/Orf1 region and seven different primer--probe sets for the N region.

Results and Discussion {#sec2}
======================

Validation of the RT-qPCR Assay {#sec2.1}
-------------------------------

The negative control did not yield a Ct value, indicating that the reaction was performed aseptically. The standard curve from the E gene primer--probe set confirmed that the reaction was performed correctly. The *R*^2^ value of the standard curve was 0.999, and the calculated amplification efficiency was 101.6%, indicating that the RT-qPCR reaction was performed under optimal conditions. The viral concentrations of supernatant and cell lysate were determined using the E gene-based assay ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Comparative Analysis of Ct Values Obtained from the Representative Experiment by Employing Each Primer--Probe Set

                                                        1.5 × 10^4^ copies   1.5 × 10^3^ copies   1.5 × 10^2^ copies                      1.5 × 10^1^ copies                      NTC                                                                                                                                                                                                     
  -------------- ------------------ ----------- ------- -------------------- -------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- -----
  60             N                  China CDC   N       24.01                0.062                26.96                                   0.049                                   30.46                                   0.534                                   34.86                                   0.119                                   N/A                                     N/A
  HKU            HKU-N              26.00       0.055   29.45                0.083                33.17                                   0.178                                   35.43                                   0.902                                   N/A                                     N/A                                                                             
  Japan NIID     NIID_2019-nCOV_N   23.09       0.053   26.56                0.150                29.5                                    0.199                                   33.13                                   0.954                                   N/A                                     N/A                                                                             
  Thailand NIH   WH-NIC N           28.64       0.058   31.89                0.237                35.26                                   0.200                                   38.13                                   0.885                                   N/A                                     N/A                                                                             
  US CDC         2019-nCoV_N1       24.25       0.185   27.50                0.095                30.57                                   0.445                                   34.71                                   0.770                                   N/A                                     N/A                                                                             
  2019-nCoV_N2   22.88              0.097       26.12   0.133                29.26                0.900                                   33.14                                   1.822                                   N/A                                     N/A                                                                                                                     
  2019-nCoV_N3   22.64              0.082       26.01   0.112                29.42                0.260                                   33.09                                   0.857                                   N/A                                     N/A                                                                                                                     
  RdRp/Orf1      China CDC          ORF1ab      27.33   0.085                30.33                0.061                                   33.61                                   0.117                                   36.85                                   0.255                                   N/A                                     N/A                                     
  Charité        RdRp_SARSr         31.89       0.115   35.14                0.050                38.57                                   0.707                                   43.00[b](#t1fn2){ref-type="table-fn"}   1.959[b](#t1fn2){ref-type="table-fn"}   N/A                                     N/A                                                                             
  HKU            HKU-ORF1b-nsp14    29.04       0.217   32.03                0.206                35.33                                   0.446                                   38.97                                   0.594                                   N/A                                     N/A                                                                             
  58             N                  China CDC   N       25.07                0.129                28.59                                   0.165                                   33.72                                   0.785                                   35.49                                   0.140                                   38.06[a](#t1fn1){ref-type="table-fn"}   \-
  HKU            HKU-N              26.73       0.040   29.85                0.192                34.80                                   0.287                                   37.69                                   0.896                                   N/A                                     N/A                                                                             
  Japan NIID     NIID_2019-nCOV_N   23.40       0.021   27.08                0.080                31.79                                   0.278                                   34.66                                   0.181                                   N/A                                     N/A                                                                             
  Thailand NIH   WH-NIC N           26.96       0.078   30.37                0.093                34.91                                   0.379                                   35.74                                   0.465                                   36.98[b](#t1fn2){ref-type="table-fn"}   0.667[b](#t1fn2){ref-type="table-fn"}                                           
  US CDC         2019-nCoV_N1       24.80       0.035   28.93                0.145                32.23                                   0.150                                   36.17                                   1.483                                   N/A                                     N/A                                                                             
  2019-nCoV_N2   24.37              0.040       28.08   0.491                31.37                0.433                                   35.05                                   0.577                                   N/A                                     N/A                                                                                                                     
  2019-nCoV_N3   24.57              0.047       27.51   0.158                31.83                0.320                                   33.99                                   0.479                                   N/A                                     N/A                                                                                                                     
  RdRp/Orf1      China CDC          ORF1ab      24.12   0.064                27.81                0.104                                   32.13                                   0.631                                   35.21                                   0.951                                   N/A                                     N/A                                     
  Charité        RdRp_SARSr         27.34       0.266   31.19                0.248                35.94[b](#t1fn2){ref-type="table-fn"}   0.580[b](#t1fn2){ref-type="table-fn"}   N/A                                     N/A                                     N/A                                     N/A                                                                             
  HKU            HKU-ORF1b-nsp14    24.56       0.053   28.12                0.153                32.84                                   0.046                                   35.51                                   0.725                                   N/A                                     N/A                                                                             
  55             N                  China CDC   N       25.26                0.086                29.56                                   0.201                                   33.11                                   0.023                                   36.05                                   0.700                                   N/A                                     N/A
  HKU            HKU-N              26.03       0.153   30.89                0.307                33.71                                   0.230                                   36.32                                   0.497                                   N/A                                     N/A                                                                             
  Japan NIID     NIID_2019-nCOV_N   24.13       0.070   28.70                0.140                31.44                                   0.180                                   35.17                                   1.104                                   N/A                                     N/A                                                                             
  Thailand NIH   WH-NIC N           26.09       0.021   30.83                0.363                33.32                                   0.317                                   35.79                                   0.430                                   N/A                                     N/A                                                                             
  US CDC         2019-nCoV_N1       24.84       0.232   29.85                0.364                32.17                                   0.075                                   35.51                                   0.905                                   N/A                                     N/A                                                                             
  2019-nCoV_N2   25.34              0.171       30.55   0.103                32.95                0.143                                   35.32                                   0.332                                   N/A                                     N/A                                                                                                                     
  2019-nCoV_N3   24.53              0.046       28.99   0.176                31.58                0.349                                   34.89                                   0.870                                   37.11[a](#t1fn1){ref-type="table-fn"}   \-                                                                                                                      
  RdRp/Orf1      China CDC          ORF1ab      24.34   0.023                28.14                0.134                                   31.86                                   0.407                                   34.10                                   0.653                                   N/A                                     N/A                                     
  Charité        RdRp_SARSr         28.24       0.141   33.12                0.612                36.09                                   0.097                                   38.00[b](#t1fn2){ref-type="table-fn"}   1.089[b](#t1fn2){ref-type="table-fn"}   N/A                                     N/A                                                                             
  HKU            HKU-ORF1b-nsp14    24.51       0.139   28.34                0.187                31.43                                   0.778                                   35.38                                   1.650                                   N/A                                     N/A                                                                             

The assay showed a positive signal from a single reaction of the triplicate.

The assay showed positive signals from the two reactions of the triplicate.

N Assays {#sec2.2}
--------

The Ct values of N (China CDC), HKU-N (HKU), NIID_2019-nCOV_N (Japan NIID), WH-NIC N (Thailand NIH), and 2019-nCoV_N1, -N2, and -N3 (US CDC) obtained from a low concentration of RNA (15 copies/reaction) were 34.86, 35.43, 33.13, 38.13, 34.71, 33.14, and 33.09, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The Ct values of 2019-nCoV_N2 and -N3 (US CDC) and NIID_2019-nCOV_N (Japan NIID) sets were similar to each other, and these sets could be regarded as the most sensitive. The assay based on 2019-nCoV_N1 (USA CDC) and N (China CDC) was moderately sensitive: these sets had higher Ct values than the most sensitive sets, but the Ct values obtained from the low concentration (15 copies/reaction) were still within the cutoff value (Ct \< 37). The WH-NIC N (Thailand NIH) set was less sensitive than other sets, with a Ct value at low concentration (15 copies/reaction) close to the cutoff value (Ct \< 38). The *R*^2^ values from N (China CDC), HKU-N (HKU), NIID_2019-nCOV_N (Japan NIID), WH-NIC N (Thailand NIH), and 2019-nCoV_N1, -N2, and -N3 (US CDC) were 0.989, 0.980, 0.987, 0.987, 0.986, 0.952, and 0.991, respectively. The calculated amplification efficiencies of N (China CDC), HKU-N (HKU), NIID_2019-nCOV_N (Japan NIID), WH-NIC N (Thailand NIH), and 2019-nCoV_N1, -N2, and -N3 (US CDC) were 89.4, 105.3, 100.7, 106.2, 95.2, 97.3, and 93.9, respectively.

According to the mean Ct of RT-qPCR analysis for the N assay in this study, 2019-nCoV_N1 and -N3 (US CDC) seemed to be sensitive amplifications ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). However, nonspecific amplification with those sets was partly observed. The nonspecific amplification was confirmed by the melting curve analysis ([Figure S5a](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). The electrophoresis analysis showed nonspecific amplification at lower positions (Lane 1, [Figure S5b](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)) than the result of specific amplification with the 2019-nCoV_N1 (US CDC) set. The RT-qPCR analysis for the N assay using the NIID_2019-nCOV_N (Japan NIID) set showed stable and specific amplification at the recommended extension temperature, 60 °C ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c), although there was a mismatched sequence in the region of the reverse primer. We had previously compared the performance of RT-qPCR analysis for the N assay using the original and corrected set (sequence of reverse primer (5′ → 3′): TGG CAC CTG TGT AGG TCA AC) of NIID_2019-nCOV_N set. Interestingly, there was no significant difference in amplification between the original and corrected set of NIID_2019-nCOV_N (data not shown). Not only NIID_2019-nCOV_N (Japan NIID) but also 2019-nCoV_N2 (US CDC) showed proper amplification at all reaction temperatures without nonspecific amplification ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, and [3](#fig3){ref-type="fig"}). The extension temperature (55 °C) of the 2019-nCoV_N2 set was previously recommended from the US CDC. The mean Ct values of RT-qPCR analysis using the 2019-nCoV_N2 set showed that 60 °C was slightly more effective than 55 and 58 °C in the present study. Therefore, NIID_2019-nCOV_N (Japan NIID) and 2019-nCoV_N2 (US CDC) sets should be optimal for SARS-CoV-2 by RT-qPCR assay of the N gene.

![Representative amplification curves of fluorescence intensity against PCR cycle with each primer--probe set (amplification is performed at 60 °C). (a) N (China CDC), (b) HKU-N (HKU), (c) NIID_2019-nCOV_N (Japan NIID), (d) WH-NIC N (Thailand NIH), (e) 2019-nCoV_N1 (US CDC), (f) 2019-nCoV_N2 (US CDC), (g) 2019-nCoV_N3 (US CDC), (h) ORF1ab (China CDC), (i) RdRp_SARSr (Charité), and (j) HKU-ORF1b-nsp14 (HKU).](id0c00464_0002){#fig1}

![Representative amplification curves of fluorescence intensity against PCR cycle with each primer--probe set (amplification is performed at 58 °C). (a) N (China CDC), (b) HKU-N (HKU), (c) NIID_2019-nCOV_N (Japan NIID), (d) WH-NIC N (Thailand NIH), (e) 2019-nCoV_N1 (US CDC), (f) 2019-nCoV_N2 (US CDC), (g) 2019-nCoV_N3 (US CDC), (h) ORF1ab (China CDC), (i) RdRp_SARSr (Charité), and (j) HKU-ORF1b-nsp14 (HKU).](id0c00464_0003){#fig2}

![Representative amplification curves of fluorescence intensity against PCR cycle with each primer--probe set (amplification is performed at 55 °C). (a) N (China CDC), (b) HKU-N (HKU), (c) NIID_2019-nCOV_N (Japan NIID), (d) WH-NIC N (Thailand NIH), (e) 2019-nCoV_N1 (US CDC), (f) 2019-nCoV_N2 (US CDC), (g) 2019-nCoV_N3 (US CDC), (h) ORF1ab (China CDC), (i) RdRp_SARSr (Charité), and (j) HKU-ORF1b-nsp14 (HKU)](id0c00464_0004){#fig3}

RdRp/Orf1 Assays {#sec2.3}
----------------

The mean Ct values of RdRp_SARSr (Charité), HKU-ORF1b-nsp14 (HKU), and ORF1ab (China CDC) obtained from a low concentration of RNA (15 copies/reaction) were 43.00, 38.97, and 36.85, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The assay with the RdRp_SARSr (Charité) set yielded a positive signal from the two reactions of the triplicate set at a concentration of 15 copies/reaction. The assay with HKU-ORF1b-nsp14 (HKU) and ORF1ab (China CDC) sets yielded positive signals at a concentration of 1.5 copies/reaction (data not shown). The *R*^2^ values from RdRp_SARSr (Charité), HKU-ORF1b-nsp14 (HKU), and ORF1ab (China CDC) were 0.983, 0.997, and 0.997, respectively. The calculated amplification efficiencies of RdRp_SARSr (Charité), HKU-ORF1b-nsp14 (HKU), and ORF1ab (China CDC) were 101.6%, 96.1%, and 109.8%, respectively.

According to the mean Ct values of RT-qPCR analysis for the RdRp/Orf1 assay in this study, ORF1ab (China CDC) seemed to have sensitive amplification ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). In the case of the ORF1ab (China CDC) set, the extension temperature was not recommended by the China CDC. From the mean Ct values of RT-qPCR analysis, the ORF1ab set showed slightly higher specific and sensitive amplification at 55 °C than at 58 and 60 °C. Not only ORF1ab (China CDC) but also HKU-ORF1b-nsp14 (HKU) showed proper amplification at all reaction temperatures without nonspecific amplification ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, [2](#fig2){ref-type="fig"}b, and [3](#fig3){ref-type="fig"}b). The extension temperature (60 °C) of the HKU-ORF1b-nsp14 set was previously recommended from HKU. The mean Ct values of RT-qPCR analysis using the HKU-ORF1b-nsp14 set showed that 55 °C was slightly more effective than 58 and 60 °C in the present study. On the other hand, the RdRp_SARSr (Charité) set shows less effective amplification than the other two primer sets at all reaction temperatures including their recommended extension temperature (58 °C). Unexpected amplifications from NTC samples were observed with the RdRp_SARSr (Charité) set. The electrophoresis and melting curve analysis showed nonspecific amplification at lower positions (Lane 5, [Figure S5b](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)) and temperatures ([Figure S5a](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)) than the result of specific amplification with the RdRP_SARSr (Charité) set. Only the RdRp_SARSr (Charité) set yielded positive signals from the two reactions of the triplicate at a concentration of 15 copies/reaction, whereas the other two primer sets showed stable positive signals. Therefore, the ORF1ab (China CDC) set should be optimal for the RdRp/Orf1 assay.

Laboratory Confirmation Using Clinical Samples {#sec2.4}
----------------------------------------------

To confirm reliable primer--probe sets for the N and RdRp/Orf1 assays, the upper respiratory tract specimens of COVID-19 patients (*n* = 6) and healthy subjects (*n* = 9) were used for RT-qPCR analysis ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, [Table S2, and Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). The mean Ct value of the NIID_2019-nCOV_N set was slightly smaller than that of the 2019-nCoV_N2 set. The limit of the detection level (4.0 × 10^1^ copies/reaction in Patient 5) of the NIID_2019-nCoV N set in the triplicate assay was better than that of the 2019-nCoV_N2 set ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The 2019-nCoV_N2 set caused nonspecific amplification in the upper respiratory tract specimens of the healthy subject (N5) to occur ([Figure S6b](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). Therefore, the NIID_2019-nCOV_N (Japan NIID) sets should be optimal for laboratory confirmation of SARS-CoV-2 by the RT-qPCR assay of the N gene without cross-reactivity for hCoV-229E, hCoV-OC43, and MERS-CoV RNA ([Figure S7a](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). The sequence variation at the binding sites of the NIID_2019-nCOV_N (Japan NIID) primer--probe set was investigated with 3,323 SARS-CoV-2 genomes from GISAID. The frequency of mismatch nucleotide was from 0.03% to 0.42% at 15 positions, excluding the mismatched sequence in the reverse primer (C → G substitution) already mentioned above ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)).

###### Comparative analysis of Ct values for each RNA extracted from clinical samples of COVID-19 patients

                                                           N                                       RdRp/Orf1                                                                                                                                                                                                       
  ---------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ------- --------------------------------------- --------------------------------------- ---------------------------------------
  patient 1 (P1)   5.3 × 10^5^                             22.22                                   0.012                                   23.42                                   0.183                                   25.17   0.191                                   25.29                                   0.225
  5.3 × 10^4^      26.86                                   0.017                                   27.13                                   0.117                                   29.85                                   0.195   30.31                                   0.154                                   
  5.3 × 10^3^      31.88                                   0.242                                   30.99                                   0.102                                   35.50                                   0.644   36.00[b](#t2fn2){ref-type="table-fn"}   0.771[b](#t2fn2){ref-type="table-fn"}   
  5.3 × 10^2^      35.60                                   0.544                                   33.65                                   0.564                                   37.37[a](#t2fn1){ref-type="table-fn"}           36.72[a](#t2fn1){ref-type="table-fn"}                                           
  5.3 × 10^1^      N/A                                     N/A                                     38.27                                   1.421                                   N/A                                     N/A     N/A                                     N/A                                     
  5.3 × 10^0^      N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  patient 2 (P2)   4.3 × 10^3^                             30.26                                   0.029                                   33.47                                   0.116                                   31.93   0.324                                   31.34                                   0.164
  4.3 × 10^2^      33.14                                   0.310                                   37.63                                   0.136                                   37.61                                   2.780   35.04                                   1.000                                   
  4.3 × 10^1^      36.19[b](#t2fn2){ref-type="table-fn"}   0.021[b](#t2fn2){ref-type="table-fn"}   39.34[b](#t2fn2){ref-type="table-fn"}   0.806[b](#t2fn2){ref-type="table-fn"}   39.66[a](#t2fn1){ref-type="table-fn"}           37.37[a](#t2fn1){ref-type="table-fn"}                                           
  4.3 × 10^0^      N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  4.3 × 10^--1^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  4.3 × 10^--2^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  patient 3 (P3)   5.9 × 10^3^                             29.88                                   0.252                                   31.18                                   0.168                                   32.06   0.260                                   31.48                                   0.794
  5.9 × 10^2^      33.37                                   0.137                                   35.65                                   0.607                                   36.89                                   0.893   36.68[b](#t2fn2){ref-type="table-fn"}   0.325[b](#t2fn2){ref-type="table-fn"}   
  5.9 × 10^1^      N/A                                     N/A                                     38.51                                   0.480                                   N/A                                     N/A     N/A                                     N/A                                     
  5.9 × 10^0^      N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  5.9 × 10^--1^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  5.9 × 10^--2^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  patient 4 (P4)   8.7 × 10^3^                             28.63                                   0.183                                   31.74                                   0.404                                   29.52   0.232                                   29.33                                   0.181
  8.7 × 10^2^      32.17                                   0.365                                   36.43                                   1.703                                   33.46                                   0.359   31.94                                   0.515                                   
  8.7 × 10^1^      35.43[a](#t2fn1){ref-type="table-fn"}                                           41.15[b](#t2fn2){ref-type="table-fn"}   2.885[b](#t2fn2){ref-type="table-fn"}   36.29[a](#t2fn1){ref-type="table-fn"}           36.09[a](#t2fn1){ref-type="table-fn"}                                           
  8.7 × 10^0^      N/A                                     N/A                                     40.76[a](#t2fn1){ref-type="table-fn"}                                           N/A                                     N/A     N/A                                     N/A                                     
  8.7 × 10^--1^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  8.7 × 10^--2^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  patient 5 (P5)   4.0 × 10^2^                             32.67                                   0.818                                   41.88[a](#t2fn1){ref-type="table-fn"}                                           33.80   0.614                                   32.95                                   0.601
  4.0 × 10^1^      35.59                                   0.128                                   N/A                                     N/A                                     34.41[a](#t2fn1){ref-type="table-fn"}           36.08[b](#t2fn2){ref-type="table-fn"}   0.120[b](#t2fn2){ref-type="table-fn"}   
  4.0 × 10^0^      N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  4.0 × 10^--1^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  4.0 × 10^--2^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  4.0 × 10^--3^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  patient 6 (P6)   6.5 × 10^1^                             36.71[a](#t2fn1){ref-type="table-fn"}                                           37.20[b](#t2fn2){ref-type="table-fn"}   0.205[b](#t2fn2){ref-type="table-fn"}   36.08   0.965                                   37.52[b](#t2fn2){ref-type="table-fn"}   1.252[b](#t2fn2){ref-type="table-fn"}
  6.5 × 10^0^      N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     36.04[a](#t2fn1){ref-type="table-fn"}                                           
  6.5 × 10^--1^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  6.5 × 10^--2^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  6.5 × 10^--3^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  6.5 × 10^--4^    N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     
  NTC              N/A                                     N/A                                     N/A                                     N/A                                     N/A                                     N/A     N/A                                     N/A                                     

The assay showed a positive signal from a single reaction of the triplicate.

The assay showed positive signals from the two reactions of the triplicate.

![Amplification curves of fluorescence intensity against the PCR cycle with the RNAs extracted from clinical samples of COVID-19 patients. (a) NIID_2019-nCOV_N (Japan NIID), (b) 2019-nCoV_N2 (US CDC), (c) ORF1ab (China CDC), and (d) HKU-ORF1b-nsp14 (HKU).](id0c00464_0005){#fig4}

In the case of the RdRp/Orf1 assay using clinical samples, there was no significant difference in mean Ct values between ORF1ab and HKU-ORF1b-nsp14 sets, but the ORF1ab set showed more stable amplification in the triplicate assay than the HKU-ORF1b-nsp14 set ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Therefore, the ORF1ab (China CDC) set should be optimal for laboratory confirmation of SARS-CoV-2 for the RdRp/Orf1 assay without cross-reactivity for hCoV-229E, hCoV-OC43, and MERS-CoV RNA ([Figure S7b](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). According to the previous study by Vogels et al., 2 mismatches (\>0.1%) have been reported at the binding sites of the ORF1ab (China CDC) primer--probe set.^[@ref17]^ The calculated frequency from the comparison of 3,323 SARS-CoV-2 genomes was 0.03% at 6 positions and 1.53% at the 26th position (T → G substitution) of the probe binding site ([Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)). Although there has been no critical problem for sensitivity of those primer--probe sets in this present study, these mismatches may affect sensitivity of RT-qPCR analysis.

Conclusions {#sec3}
===========

Various primer--probe sets have been reported for the detection of SARS-CoV-2 by the RT-qPCR assay. However, the sensitivity of these assays may not be sufficient to confirm suspicious patients in the early stage of SARS-CoV-2 infection. Previous studies have been reported to compare some primer--probe sets listed in the WHO for the molecular diagnosis of SARS-CoV-2.^[@ref17],[@ref18]^ In this study, we performed RT-qPCR analysis with previously reported specific primer--probe sets targeting the RdRp/Orf1 and N region of SARS-CoV-2. The NIID_2019-nCOV_N (Japan NIID) set and the ORF1ab (China CDC) set among various primer--probe sets ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) posted by the WHO represent a recommendable performance of RT-qPCR analysis for SARS-CoV-2 molecular diagnostics without nonspecific amplification and cross-reactivity for hCoV-229E, hCoV-OC43, and MERS-CoV RNA. Although some degeneracies were found at the binding sites of these primer--probe sets, there has been no critical problem for sensitivity of our recommended primer--probe sets. More precise primer--probe sets for target genes will be needed through a comparison of abundant genomes of SARS-CoV-2.

###### Information of Primers and Probes Analyzed in the Study

  target                 institute              name                                                                               type                            sequence (5′ → 3′)              position       recommended extension temperature (°C)   reference
  ---------------------- ---------------------- ---------------------------------------------------------------------------------- ------------------------------- ------------------------------- -------------- ---------------------------------------- ------------
  N                      China CDC              N-F                                                                                F                               GGG GAA CTT CTC CTG CTA GAA T   28881--28902   N/A                                      ([@ref20])
  N-R                    R                      CAG ACA TTT TGC TCT CAA GCT G                                                      28958--28979                                                                                                            
  N-P                    P                      FAM--TTG CTG CTG CTT GAC AGA TT--BHQ1[a](#t3fn1){ref-type="table-fn"}              28934--28953                                                                                                            
  HKU                    HKU-NF                 F                                                                                  TAA TCA GAC AAG GAA CTG ATT A   29145--29166                    60             ([@ref9])                                
  HKU-NR                 R                      CGA AGG TGT GAC TTC CAT G                                                          29235--29254                                                                                                            
  HKU-NP                 P                      FAM--GCA AAT TGT GCA ATT TGC GG--BHQ1[a](#t3fn1){ref-type="table-fn"}              29177--29196                                                                                                            
  Japan NIID             NIID_2019-nCOV_N\_F2   F                                                                                  AAA TTT TGG GGA CCA GGA AC      29125--29144                    60             ([@ref21])                               
  NIID_2019-nCOV_N\_R2   R                      TGG CA[G]{.ul} CTG TGT AGG TCA AC[b](#t3fn2){ref-type="table-fn"}                  29263--29282                                                                                                            
  NIID_2019-nCOV_N\_P2   P                      FAM--ATG TCG CGC ATT GGC ATG GA--BHQ1[a](#t3fn1){ref-type="table-fn"}              29222--29241                                                                                                            
  Thailand NIH           WH-NIC N-F             F                                                                                  CGT TTG GTG GAC CCT CAG AT      28320--28339                    55             ([@ref22])                               
  WH-NIC N-R             R                      CCC CAC TGC GTT CTC CAT T                                                          28358--28376                                                                                                            
  WH-NIC N-P             P                      FAM--CAA CTG GCA GTA ACC A--BHQ1[a](#t3fn1){ref-type="table-fn"}                   28341--28356                                                                                                            
  US CDC                 2019-nCoV_N1-F         F                                                                                  GAC CCC AAA ATC AGC GAA AT      28287--28306                    55             ([@ref23])                               
  2019-nCoV_N1-R         R                      TCT GGT TAC TGC CAG TTG AAT CTG                                                    28335--28358                                                                                                            
  2019-nCoV_N1-P         P                      FAM--ACC CCG CAT TAC GTT TGG TGG ACC--BHQ1[a](#t3fn1){ref-type="table-fn"}         28309--28332                                                                                                            
  2019-nCoV_N2-F         F                      TTA CAA ACA TTG GCC GCA AA                                                         29164--29183                    55                                                                                      
  2019-nCoV_N2-R         R                      GCG CGA CAT TCC GAA GAA                                                            29213--29230                                                                                                            
  2019-nCoV_N2-P         P                      FAM--ACA ATT TGC CCC CAG CGC TTC AG--BHQ1[a](#t3fn1){ref-type="table-fn"}          29188--29210                                                                                                            
  2019-nCoV_N3-F         F                      GGG AGC CTT GAA TAC ACC AAA A                                                      28681--28702                    55                                                                                      
  2019-nCoV_N3-R         R                      TGT AGC ACG ATT GCA GCA TTG                                                        28732--28752                                                                                                            
  2019-nCoV_N3-P         P                      FAM--AYC ACA TTG GCA CCC GCA ATC CTG--BHQ1[a](#t3fn1){ref-type="table-fn"}         28704--28727                                                                                                            
  RdRp/Orf1              China CDC              ORF1ab-F                                                                           F                               CCC TGT GGG TTT TAC ACT TAA     13342--13362   N/A                                      ([@ref20])
  ORF1ab-R               R                      ACG ATT GTG CAT CAG CTG A                                                          13442--13460                                                                                                            
  ORF1ab-P               P                      FAM--CCG TCT GCG GTA TGT GGA AAG GTT ATG G--BHQ1[a](#t3fn1){ref-type="table-fn"}   13377--13404                                                                                                            
  Charité                RdRp_SARSr-F           F                                                                                  GTG ARA TGG TCA TGT GTG GCG G   15431--15452                    58             ([@ref10])                               
  RdRp_SARSr-R           R                      CAR ATG TTA AAS ACA CTA TTA GCA TA                                                 15505--15530                                                                                                            
  RdRp_SARSr-P2          P                      FAM--CAG GTG GAA CCT CAT CAG GAG ATG C--BHQ1[a](#t3fn1){ref-type="table-fn"}       15470--15494                                                                                                            
  HKU                    HKU-ORF1b-nsp14F       F                                                                                  TGG GGY TTT ACR GGT AAC CT      18778--18797                    60             ([@ref9])                                
  HKU-ORF1b-nsp14R       R                      AAC RCG CTT AAC AAA GCA CTC                                                        18889--18909                                                                                                            
  HKU-ORF1b-nsp14P       P                      FAM--TAG TTG TGA TGC WAT CAT GAC TAG--BHQ1[a](#t3fn1){ref-type="table-fn"}         18849--18872                                                                                                            

FAM: 6-carboxyfluorescein; BHQ-1: Black Hole Quencher-1.

The underlined letter within NIID_2019-nCoV_NR2 indicates a mismatched site to the PCR template.

Methods {#sec4}
=======

Primer Information on qPCR {#sec4.1}
--------------------------

For comparative analysis of laboratory confirmation for SARS-CoV-2, ten primer--probe sets were selected on the basis of sequence information from six different national institutions: the Centers for Disease Control and Prevention (CDC) (USA); Charité -- Universitätsmedizin Berlin Institute of Virology (Germany), the University of Hong Kong (Hong Kong); the National Institute of Infectious Disease, Department of Virology III (Japan); China CDC (China); the National Institute of Health (Thailand). All DNA oligonucleotides were synthesized by Neoprobe (Daejeon, South Korea). Sequences of the primer--probe sets and their locations in the viral RNA (GenBank MN908947.3) are listed in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} and [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. Seven of the ten sets were derived from the N gene and the other three, from the Orf1 gene (RdRp, ORF 1b-Nsp14, and ORF 1-Nsp10). All DNA oligonucleotides were resuspended in nuclease-free water before use.

![Relative positions of RT-qPCR primer--probe sets in the SARS-CoV-2 genome. Target gene and primer sequences were obtained from the WHO Web site (<http://www.who.int>). The numbers below the amplicons indicate genome positions in SARS-CoV-2 (GenBank MN908947.3). The sets were published by China CDC (Orf1ab and N), Charité -- Universitätsmedizin Berlin Institute of Virology in Germany (RdRp_SARSr and E), the University of Hong Kong (HKU-ORF1b_nsp14 and HKU-N), USA CDC (2019-nCoV_N1, -N2, and -N3), the National Institute of Health in Thailand (WH-NIC N), and the National Institute of Infectious Disease in Japan (NIID_2019-nCoV_N). Orf1: open reading frame 1; RdRp: RNA-dependent RNA polymerase; Nsp14: nonstructural protein 14 gene; S: spike protein gene; E: envelop protein gene; N: nucleocapsid protein gene.](id0c00464_0001){#fig5}

Viral RNA Preparation {#sec4.2}
---------------------

Infection experiments were performed in a biosafety level-3 (BSL-3) laboratory. African green monkey kidney Vero cells (ATCC CCL-81) were infected with a clinical isolate of SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020 provided by Korea CDC). After 72 h, culture medium containing mature infectious virions (virus medium) was collected, and viral RNA was isolated from the culture medium using the QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany). Human coronavirus (hCoV)-229E, hCoV-OC43, and Middle East respiratory syndrome (MERS)-CoV RNA were prepared, as previously described.^[@ref19]^

Preparation of *In Vitro* Transcribed RNA Standard {#sec4.3}
--------------------------------------------------

The coding sequence of the SARS-CoV-2 Envelope (E) protein, cloned into pET21a, was PCR-amplified with the T7 promoter primer (5′--AATACGACTCACTATAG--3′, Macrogen Inc., Seoul, South Korea) and T7 terminator primer (5′--GCTAGTTATTGCTCAGCGG--3′, Macrogen Inc.) using the AccuPower PCR PreMix (-dye) kit (Bioneer Inc., Daejeon, South Korea). The PCR product was then used as the *in vitro* transcription template for the MEGAscript T7 Transcription Kit (Invitrogen Inc., CA, USA). The copy number of *in vitro* transcribed RNA was calculated from RNA concentration measured with a Quantus Fluorometer (Promega, Madison, WI, USA). Standardized amounts of *in vitro* transcribed RNA were amplified by RT-qPCR using the E primers to produce a standard curve.

RT-qPCR Analysis in N and RdRp/Orf1 {#sec4.4}
-----------------------------------

Extracted nucleic acid samples were tested for comparative analysis of SARS-CoV-2 by RT-qPCR. The N and Orf1 regions of SARS-CoV-2 were used as the target sequences for SARS-CoV-2-specific genes. Briefly, 10 μL of purified viral RNA was amplified in a 20 μL reaction solution containing 1× TaqPath 1-Step Multiplex Master Mix (Thermo Fisher Scientific INC., MA, USA) and 300 nM of primers and probes for target detection. RT-qPCR was performed in a CFX 96 touch real-time PCR detection system (Bio-Rad, Hercules, CA, USA). The RT-qPCR conditions applied in this study were as follows: UNG incubation, RT incubation, and enzyme activation were performed in series at 25 °C for 2 min, 55 °C for 10 min, and 94 °C for 3 min, respectively. Thermal cycling was then performed at 94 °C for 15 s (denaturation) and 60 °C for 30 s (annealing and amplification) for 45 cycles. All confirmatory RT-qPCR assays were performed more than three times. All mean Ct values were calculated from the three reactions of each triplicated set.

Clinical Sample Preparation {#sec4.5}
---------------------------

The upper respiratory tract specimens (naso- and oropharyngeal swabs) of COVID-19 patients (*n* = 6) and healthy subjects (*n* = 9) used in this study ([Table S2](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf)) were collected from subjects as part of the registered protocols approved by the Institutional Review Board (IRB) of Jeonbuk National University Hospital. All patients provided written informed consent (IRB registration number: CUH 2020-02-050-008). The clinical samples were stored in transport medium (eNAT; COPAN, Murrieta, CA). All samples were inactivated by heating at 100 °C for 10 min and stored at −80 °C for further analysis. Viral RNA was isolated from the clinical samples using the QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany). The copy number of extracted RNA from the clinical samples was calculated by the method described above.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00464](https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00464?goto=supporting-info).Polyacrylamide gel electrophoresis, melting curve analysis, SARS-CoV-2 genome alignment protocols, standard curves for quantification of SARS-CoV-2 RNA, additional comparative analysis data of Ct values, amplification curves of each primer--probe set, melting curve and polyacrylamide gel analysis data, clinical characteristics of COVID-19 patients, and PCR test data with the RNAs extracted from clinical samples of healthy subjects and other coronaviruses ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00464/suppl_file/id0c00464_si_001.pdf))
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